Congress Materials – European Academy of Neurology (EAN 2025)
2025 European Academy of Neurology | June 21-24 | Helsinki, Finland
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Delphi Panel to Identify Optimal Clinical Outcome Measures (COAs) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Yusuf A. Rajabally, Giorgio Maria Boggia, Danielle Riley, Sam Riley, Judith Peatman, Maartje Mangelaars, Charlotte Gary, Chelsey Fix, Eduardo Nobile-Orazio
Analysis of Long-Term Efficacy of Nipocalimab in Myasthenia Gravis: Open-Label Extension of the Vivacity-MG3 Trial
Nicholas J. Silvestri, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren
Assessment of Patient-Reported Outcomes from the Phase 3 Vivacity-MG3 Study of Nipocalimab in gMG
Elena Cortés Vicente, Sheryl Pease, Nida Imran, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Geoffroy Coteur, Charlotte Gary, Zia Choudhry, Sindhu Ramchandran, John Vissing
Burden of remaining symptoms and fluctuations of generalized myasthenia gravis on patients’ daily lives – BEYOND study
Francesco Saccà, Sophie Lehnerer, Maria (Maya) Bonaria Uccheddu, Diana Sufragiu, Charlotte Campbell, Daisy Bridge, Sophie Pope, Camille Chassat, Gonçalo M.C. Rodrigues, Maartje Mangelaars, Wim Noel, Charlotte Gary
Comparative Efficacy of Nipocalimab and Other FcRn Blocker Therapies in Generalized Myasthenia Gravis
Saiju Jacob, Mahmoud Hashim, Brian Hutton, Kavita Gandhi, Rafal Slowik, Christopher Drudge, Antoine C El Khoury, Maria Ait Tihyaty, Mi Jun Keng, Xiwu Lin, Sumeet Singh, Nils Erik Gilhus
Comprehensive analysis of motor endplate pathology in AChR-Ab-positive myasthenia gravis
Corinna Preusse, Andreas Meisel, Paolo Doksani, Carsten Dittmayer, Markus Schuelke, Jens-Carsten Rückert, Matthias Pumberger, Friederike Schömig, Werner Stenzel, Sarah Hoffmann
Efficacy of Nipocalimab in Adult Patients with Moderate-to-severe Ocular Manifestations of gMG in Phase 3 VIVACITY-MG3
Kristl G. Claeys, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Sheryl Pease, Charlotte Gary, Zia Choudhry, Sindhu Ramchandren
Efficacy of Nipocalimab in Open-Label Extension in Patients Transitioned from Placebo: Results from Vivacity-MG3 Trial
Kristl G. Claeys, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren, Tuan Vu
Fatigue Assessed by Neuro-QoL in Phase 3 Vivacity-MG3 Trial of Nipocalimab vs Placebo in Generalized Myasthenia Gravis
John Vissing, Kavita Gandhi, Sheryl Pease, Nida Imran, Maria Ait-Tihyaty, Ibrahim Turkoz, Geoffroy Coteur, Charlotte Gary, Zia Chaudhry, Sindhu Ramchandran
Healthcare resource utilization and costs associated with exacerbation or crisis in generalized myasthenia gravis
Nicholas J. Silvestri, Kavita Gandhi, Martin Cloutier, Geoffroy Coteur, Maryia Zhdanava, Antoine C El Khoury, Porpong Boonmak, Anabelle Tardif-Samson, Maria Ait-Thiyaty, Yuxi Wang, Zia Choudhry, Kavita Grover
Predictors of Composite Response in MG—Based on Patient and Clinician-Reported Assessments—in Vivacity-MG3 Phase 3 Trial
Elena Cortés-Vicente, Ibrahim Turkoz, Maria Ait-Tihyaty, Kavita Gandhi, Zia Choudhry, Bernie Sattin, Wim Noel, Charlotte Gary, Mazen M. Dimachkie
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.